CIMG Inc. Reports Record Q1 Revenue, Expands Digital Asset Holdings, and Advances Strategic Business Transformation

HONG KONG, March 25, 2026 — CIMG Inc. (“CIMG” or the “Company”; Nasdaq: IMG), a leader in digital health and sales development, has announced its financial results for the three months ended December 31, 2025. The company reported a dramatic surge in revenue, a substantial increase in digital asset holdings, and significant progress in its business transformation strategy focused on the Asia market.

Key Highlights from Q1 Financial Report

• Revenue Soars: Total revenue for the quarter reached \$15,768,796, up from just \$22,853 in the same period last year. This exceptional growth is attributed to the initial commercialization and expansion into the medicine-food homology product line and computing power solutions—two new business verticals for the company.
• Digital Asset Holdings Grow: As of December 31, 2025, CIMG held 730 Bitcoins with a carrying value of \$63,978,821. This position exposes shareholders to potential upside—and downside—given the high volatility of cryptocurrency markets.
• Book Value Per Share: The company’s book value per share was approximately \$3.6 as of December 31, 2025.

Business Transformation and Strategic Progress

• Product Line Expansion: Leveraging digital marketing, CIMG achieved sales growth in its medicine-food homology products. In September 2025, it officially launched its computing power product line, offering GPU hardware devices with integrated AI data processing modules for enterprise clients. Notably, CIMG generated revenue from a contract with China Merchants Bank.
• Global Subsidiary Expansion: The company established wholly-owned subsidiaries in Shenzhen and Foshan, China, and acquired Braincon Limited (“Braincon HK”) and its subsidiary Beijing Xin Miao Shi Dai Technology Development Co., Ltd., strengthening its production, sales, and R&D capabilities in Asia.

Management Commentary and Strategic Outlook

Alice Wang, Chairman and CEO of CIMG, stated: “The Company will continue to focus on the Asia market and deepen its dual-track strategy in health consumer goods and computing power technology. We aim to expand online and offline sales for our maca and medicine-food homology products, optimize pricing and cost control, and improve gross profit margins. We will also increase R&D investment in computing power products and AI modules, aiming to grow our enterprise customer base and increase the revenue share of the computing power segment.”

• The company is actively pursuing further financing to optimize its capital structure and is strictly adhering to Nasdaq listing rules, following an appeal against a delisting decision. Management is committed to maintaining CIMG’s listing status.
• CIMG is also taking steps to strengthen its internal financial management and control systems, aiming to support the transition from business transformation toward sustainable profitability.

Risks and Potential Share Price Impact

• Cryptocurrency Exposure: The company’s significant Bitcoin holdings can materially impact financial results due to market volatility—both a risk and a potential catalyst for share price movement.
• Nasdaq Listing at Risk: CIMG has appealed a Nasdaq delisting decision; the outcome of this process could dramatically affect shareholder value.
• Business Execution: The success of the new product lines, expansion efforts, and ability to maintain compliance with listing and regulatory requirements will be critical for future valuation.

About CIMG Inc.

CIMG specializes in digital health and sales development, leveraging AI and cryptocurrencies (including Bitcoin and stablecoins) to drive business growth and maximize client value. Its client portfolio includes brands such as Kangduoy Maca-Noni, Qianmao, Huomao, and Coco-mango.

Forward-Looking Statements

This article contains forward-looking statements reflecting current expectations and subject to risks and uncertainties, including but not limited to market volatility of digital assets, regulatory changes, access to capital, competitive pressures, and the outcome of the Nasdaq appeal. Investors should refer to the company’s latest filings with the SEC for more details.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions.

View CIMG Inc. Historical chart here